Rasburicase is a recombinant urate oxidase enzyme used to rapidly reduce elevated uric acid concentrations. It is a recombinant form of the enzyme urate oxidase and catalyzes the oxidation of uric acid into allantoin, which is considerably more water-soluble and readily eliminated.
Rasburicase is primarily used to manage hyperuricemia associated with tumor lysis syndrome (TLS) in patients receiving cytotoxic chemotherapy for hematologic malignancies.
Unlike conventional small-molecule APIs, Rasburicase is a recombinant protein biological API. Therefore, its quality assessment requires biological, biochemical and protein-characterization methods.
Product Name: Rasburicase
API Category: Biological API / Recombinant Enzyme
Therapeutic Class: Antihyperuricemic Agent
Drug Class: Recombinant Urate Oxidase
CAS Number: 134774-95-5
Molecular Formula: Not applicable as a conventional small-molecule API
Molecular Weight: Approximately 34 kDa per subunit
Protein Type: Recombinant urate oxidase
Enzyme Classification: EC 1.7.3.3
Expression System: Recombinant Saccharomyces cerevisiae
Therapeutic Area: Oncology / Tumor Lysis Syndrome
Rasburicase is a tetrameric enzyme, with four identical subunits and an overall molecular mass of approximately 136 kDa for the tetramer.
Rasburicase is a recombinant form of urate oxidase. The enzyme converts uric acid into allantoin through an oxidative reaction involving molecular oxygen.
The recombinant protein is produced using genetically modified Saccharomyces cerevisiae cells. Each protein subunit has an approximate molecular weight of 34 kDa.
As a protein therapeutic, Rasburicase does not have a conventional small-molecule molecular formula, exact mass, log P or melting-point specification. Its characterization instead focuses on protein identity, purity, enzymatic activity, aggregation, structural characteristics and biological performance.
The finished pharmaceutical product is supplied as a sterile lyophilized preparation for reconstitution.
Rasburicase is used for the management and prevention of severe hyperuricemia associated with tumor lysis syndrome.
Its major pharmaceutical application is in patients with hematologic malignancies who are at risk of developing elevated uric acid levels following chemotherapy.
Applications include:
Rasburicase is particularly relevant when rapid reduction of uric acid is clinically required.
Rasburicase acts by enzymatically converting uric acid into allantoin.
Humans lack functional urate oxidase, resulting in uric acid being the final product of purine metabolism. During tumor lysis, rapid breakdown of nucleic acids can cause a substantial increase in uric acid.
Rasburicase provides urate oxidase activity and rapidly converts uric acid into allantoin, which is much more soluble in water and can therefore be eliminated more readily through the kidneys.
Rasburicase requires specialized analytical testing appropriate for a recombinant enzyme biological product.
Quality evaluation may include:
Because Rasburicase is a biological API, numerical acceptance criteria for potency, purity, aggregates and process-related impurities are product-specific and should be established according to the validated manufacturing process and applicable regulatory specification.
Rasburicase is produced using recombinant DNA technology in genetically modified Saccharomyces cerevisiae.
The manufacturing process involves controlled fermentation followed by recovery and purification of the recombinant urate oxidase protein.
Typical manufacturing controls may include:
The manufacturing process requires strict control of protein structure, enzymatic activity, purity and microbiological quality.
Rasburicase pharmaceutical formulations are supplied as sterile lyophilized material requiring controlled refrigerated storage.
For the marketed rasburicase product, vials are stored at 2–8°C and protected from light. The product should not be frozen.
After reconstitution, handling and storage should follow the applicable approved product instructions and validated stability conditions.
Bulk Rasburicase API should be stored and transported under validated temperature-controlled conditions established from stability data.
Typical documentation for Rasburicase biological API may include:
Rasburicase is a complex recombinant enzyme requiring specialized biological manufacturing, purification and analytical characterization.
A qualified Rasburicase API Manufacturer in India should maintain strict controls over recombinant cell culture, protein recovery, purification, enzymatic activity, aggregation, purity, microbiological quality and temperature-controlled storage.
Because Rasburicase is a biological API rather than a conventional small molecule, product quality should be evaluated through validated protein and biological assays appropriate to the manufacturing process and intended pharmaceutical application.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Individual Impurity | NMT 0.10% |
| Total Impurities | NMT 0.50% |